Janos Tibor Kodra

This inventor holds 28 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Insulin Derivatives. Top assignees: Novo Nordisk A/s, Novo Nordick A/s. Active years: 2003-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Janos Tibor Kodra. Retrieved from https://idiyas.com/inventor/janos-tibor-kodra

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 7)

% Patents Active = 46.4

CIPO Patents = 1 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 7.0

ph-index = 10

Forward Citations = 554(Granted Patents)

Location History:

Kobenhavn, DK (2005)
Koebenhavn O, DK (2014)
Bagsvaerd, DK (2014)
Cophenhagen, DK (2015)
Copenhagen, DK (2003 - 2020)
Koebenhavn Oe, DK (2015 - 2021)
Koebenhavn, DK (2019 - 2022)

Company Filing History:

Years Active: 2003-2022

Loading Chart...

Areas of Expertise:

Insulin Derivatives

GLP-1 Compounds

Glucagon Antagonists

Protease Stabilized Analogues

Aryl Carbonyl Derivatives

Long-Acting Gastrin

Therapeutic Agents

Acylated Insulin Analogues

Double-Acylated GLP-1

CGRP Derivatives

Non-Peptide GLP-1 Agonists

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11471537 - Oligomer extended insulin-Fc conjugates (2022-10-18),

2. 10946074 - GLP-1 derivatives and uses thereof (2021-03-16),

3. 10822385 - EGF(A) analogues with fatty acid substituents (2020-11-03),

4. 10689429 - Double-acylated GLP-1 compounds (2020-06-23),

5. 10259856 - Protease stabilized acylated insulin analogues (2019-04-16),

6. 9708383 - Double-acylated GLP-1 derivatives (2017-07-18),

7. 9688737 - Protease stabilized acylated insulin analogues (2017-06-27),

8. 9657079 - Truncated GLP-1 derivatives and their therapeutical use (2017-05-23),

9. RE46170 - Insulin derivatives (2016-10-03),

10. RE45670 - Aryl carbonyl derivatives as therapeutic agents (2015-09-14),

11. 9040660 - Long-acting gastrin derivatives (2015-05-26),

12. 9035020 - Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids (2015-05-19),

13. 8962794 - Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids (2015-02-24),

14. 8933021 - Insulin derivative (2015-01-13),

15. 8835379 - Derivatives of CGRP (2014-09-16),

Title: Janos Tibor Kodra: Pioneering Innovations in Copenhagen

Introduction:

Janos Tibor Kodra, a visionary inventor based in Copenhagen, Denmark, has left an indelible mark on the world of technology with his passion for innovation and relentless pursuit of excellence. His 28 patents attest to his remarkable contributions to the field of protein conjugates and GLP-1 analogues, revolutionizing the treatment of metabolic disorders.

Latest Patents:

Kodra's latest patents include groundbreaking inventions such as the "Oligomer extended insulin-Fc conjugates." This innovation focuses on extending insulins with covalently attached Fc monomer polypeptides for treating metabolic disorders. Additionally, his invention of "GLP-1 derivatives and uses thereof" showcases stable compounds for treating type 2 diabetes, emphasizing the importance of maintaining receptor activation while resisting degradation.

Career Highlights:

Having worked at renowned companies like Novo Nordisk A/S, Kodra has demonstrated his expertise in the pharmaceutical industry. His innovative solutions have paved the way for advancements in healthcare, inspiring novel approaches to combatting metabolic conditions. Kodra's dedication to pushing the boundaries of science has earned him recognition as a trailblazer in his field.

Collaborations:

Throughout his career, Kodra has collaborated with esteemed professionals such as Jesper F. Lau and Peter Madsen. Together, they have spearheaded research initiatives that have led to impactful breakthroughs in pharmaceutical development. Their collective efforts have enriched the industry and fostered a culture of collaboration and innovation.

Conclusion:

Janos Tibor Kodra's unwavering commitment to innovation and transformative research serves as a beacon for aspiring inventors worldwide. His pioneering spirit continues to shape the future of technology and inspire a new generation of visionaries to push the boundaries of what is possible in the realm of metabolic disorder treatment.

Profile summary based on public USPTO records.